And like Omicron, it appears to largely escape the immunity created by vaccines. A booster shot restores protection, making illness after infection about 74% less likely.
BA.2 is also resistant to some treatments, including sotrovimab, the monoclonal antibody that’s currently being used against Omicron.
The findings were posted Wednesday as a preprint study on the bioRxiv server, before peer review. Normally, before a study is published in medical journal, it is scrutinized by independent experts. Preprints allow research to be shared more quickly, but they are posted before that additional layer of review.
“It might be, from a human’s perspective, a worse virus than BA.1 and might be able to transmit better and cause worse disease,” says Dr. Daniel Rhoads, section head of microbiology at the Cleveland Clinic in Ohio. Rhoads reviewed the study but was not involved in the research.
The US Centers for Disease Control and Prevention is keeping close watch on BA.2, said its director, Dr. Rochelle Walensky.
“There is no evidence that the BA.2 lineage is more severe than the BA.1 lineage. CDC continues to monitor variants that are circulating both domestically and internationally,” she said Friday. “We will continue to monitor emerging data on disease severity in humans and findings from papers like this conducted in laboratory settings.”
BA.2 is highly mutated compared with the original Covid-causing virus that emerged in Wuhan, China. It also has dozens of gene changes that are different from the original Omicron strain, making it as distinct from the most recent pandemic virus as the Alpha, Beta, Gamma and Delta variants were from each other.
Kei Sato, a researcher at the University of Tokyo who conducted the study, argues that these findings prove that BA.2 should not be considered a type of Omicron and that it needs to be more closely monitored.
“As you may know, BA.2 is called ‘stealth Omicron,’ ” Sato told CNN. That’s because it doesn’t show up on PCR tests as an S-gene target failure, the way Omicron does. Labs therefore have to take an extra step and sequence the virus to find this variant.
“Establishing a method to detect BA.2 specifically would be the first thing” many countries need to do, he says.
“It looks like we might be looking at a new Greek letter here,” agreed Deborah Fuller, a virologist at the University of Washington School of Medicine, who reviewed the study but was not part of the research.
Mixed real-world data on subvariant’s severity
BA.2 has been estimated to be about 30% more contagious than Omicron, according to the World Health Organization. It has been detected in 74 countries and 47 US states.
The US Centers for Disease Control and Prevention estimates that about 4% of Americans with Covid-19 now have infections caused by BA.2, but many other parts of the world have more experience with this variant. It has become dominant in at least 10 other countries: Bangladesh, Brunei, China, Denmark, Guam, India, Montenegro, Nepal, Pakistan and the Philippines, according to World Health Organization’s weekly epidemiological report.
However, there’s mixed evidence on the severity of BA.2 in the real world. Hospitalizations continue to decline in countries where BA.2 has gained a foothold, like South Africa and the UK. But in Denmark, where BA.2 has become the leading cause of infections, hospitalizations and deaths are rising, according to WHO.
Resistant to monoclonal antibody treatments
The new study found that BA.2 can copy itself in cells more quickly than BA.1, the original version of Omicron. It’s also more adept at causing cells to stick together. This allows the virus to create larger clumps of cells, called syncytia, than BA.1. That’s concerning because these clumps then become factories for churning out more copies of the virus. Delta was also good at creating syncytia, which is thought to be one reason it was so destructive to the lungs.
When the researchers infected hamsters with BA.2 and BA.1, the animals infected with BA.2 got sicker and had worse lung function. In tissues samples, the lungs of BA.2-infected hamsters had more damage than those infected by BA.1.
Similar to the original Omicron, BA.2 was capable of breaking through antibodies in the blood of people who’d been vaccinated against Covid-19. It was also resistant to the antibodies of people who’d been infected with Covid-19 early in the pandemic, including Alpha and Delta. And BA.2 was almost completely resistant to some monoclonal antibody treatments.
But there was a bright spot: Antibodies in the blood of people who’d recently had Omicron also seemed to have some protection against BA.2, especially if they’d also been vaccinated.
And that raises an important point, Fuller says. Even though BA.2 seems more contagious and pathogenic than Omicron, it may not wind up causing a more devastating wave of Covid-19 infections.
“One of the caveats that we have to think about as we get new variants that might seem more dangerous is the fact that there’s two sides to the story,” Fuller says.
The virus matters, she says, but as its would-be hosts, so do we.
“Our immune system is evolving as well. And so that’s pushing back on things,” she said.
Right now, she says, we’re in a race against the virus, and the key question is, who’s in the lead?
“What we will ultimately want is to have the host be ahead of the virus. In other words, our immunity, be a step ahead of the next variant that comes out, and I don’t know that we’re quite there yet,” she said.
For that reason, Fuller says, she feels like it’s not quite time for communities to lift mask mandates.
“Before this thing came out, we were about 10 feet away from the finish line,” she said. “Taking off the masks now is not a good idea. It’s just going to extend it. Let’s get to the finish line.”